Seven other companies are scheduled for the week of
The manager is
On the Nasdaq, SMLR scheduled a
SMLR leases and doesn't sell, to internists and primary care physicians. Lease revenue for the nine months ended September '13 was up 114% to
The rating on SMLR is neutral but with a watch.
The stock market likes recurring lease revenue, and SMLR appears on its way to developing a meaningful recurring revenue stream. If SMLR can appoach break even then company's stock will be a lot higher.
SMLR is an emerging medical risk-assessment company, with a device that measures blood flow at the extremeties.
SMLR has one patented and
SMLR began commercially leasing FloChec(TM) in
FloChec(TM) is a four-minute in-office blood flow test. Healthcare providers can use blood flow measurements as part of their examinations of a patient's vascular condition, including assessments of patients who have vascular disease.
FloChec(TM) is used in the office setting to allow providers to measure arterial blood flow in the extremities and is a useful tool for internists and primary care physicians for whom it was previously impractical to conduct blood flow measurements.
SMLR has been issued one patent for its apparatus and method, U.S. Patent No. 7,628,760, which expires
However, any interests it may have had in such 510(k) clearance were subsequently assigned to SMLR and it did not manufacture any products for its company. The Class II Medical Device designation means that FloChec(TM) is a commercial device and is currently being sold in
The principal competitor for FloChec(TM) is the standard blood pressure cuff ankle-brachial index, or
FloChec(TM) does not include a blood pressure cuff. SMLR is not aware of another product that performs digital
There are several companies that manufacture the traditional
GPG SSF Investments? 10.2%
Eric Semler? 18.6%
Dr. & Mrs. Semler? 26.8%
Dinesh Gupta? 5.5%
Dr. Douglas Murphy-Chutorian? 8.4%
Use of proceeds
SMLR expects to net
working capital and general corporate purposes.
54% of the proceeds to invest in SMLR's sales and marketing efforts to commercialize its product, and use 32% for general and administrative expenditures, including addressing compliance with U.S. public company requirements, such as hiring additional personnel and investing in SMLR's corporate infrastructure.